united kingdomen
China on-site: trade war risk and healthcare momentum

China on-site: trade war risk and healthcare momentum

12-06-2018 | Insight

How should Chinese equity investors deal with trade war risk? In this edition of our China on-site series, we show how we address this hotly debated issue and also highlight the strong momentum in the Chinese healthcare sector.

  • Victoria  Mio
    Victoria
    Mio
    CIO China, co-Head Asia Pacific Equities, Fund Manager Robeco Chinese Equities
  • Hauke Ris
    Hauke
    Ris
    Client Portfolio Manager Asia-Pacific Equity
  • Jie Lu
    Jie
    Lu
    Head of Research China

Speed read

  • Despite strong tensions, a full-blown trade war is not our base case
  • Domestic companies are little impacted by Trump’s protectionist measures
  • China’s healthcare spending is one of the lowest, leaving vast growth potential

Concern: how to deal with trade war risk?

Even though trade tensions between the US and China have increased, a full-blown trade war is not our base-case scenario.

Over the past few months, US president Trump has made good on his campaign promises, having taken various measures to protect US industries. His actions, of which an increase in tariffs on aluminum is but one example, mainly appear to be targeting China, although lately Europe is more in the picture as well.

In our view, Trump is putting his bargaining chips on the table, while China is responding in a very measured way, aiming to de-escalate the situation and stressing the importance of free trade. Recently, the two countries reached consensus to reduce the US trade deficit with China by China importing more US products such as oilseeds, beef (figure 1), energy, automobiles, and aircraft.

Stay informed on our latest insights with monthly mail updates
Stay informed on our latest insights with monthly mail updates
Subscribe

Figure 1: Room of China to increase Beef Imports from the US

Source Meat & Livestock Australia (MLA), USDA, Morgan Stanley Research

Ready to act

The overall impact of the US measures on trade between the US and China as well as on China’s GDP is relatively small. Still, the Chinese authorities are keeping a close eye on developments, ready to mitigate any negative consequences. In April, for example, the People’s Bank of China announced a 1%-point cut in the Reserve Requirement Ratio for major banks, releasing RMB 1,300 billion in liquidity.

Domestic focus

In our Chinese equity portfolios, we focus on domestic companies, which are little impacted by Trump’s protectionist measures. We select our stocks from within the following themes: ‘Technology & Innovation’, ‘Consumption Upgrade’, ‘Structural Reform’ and industrial innovation under the ‘Made in China 2025’ plan.

Opportunity: strong momentum in China’s healthcare sector

Although China is the world’s second largest healthcare market, its healthcare expenditure per capita is one of the lowest. This leaves a vast potential for growth, making it a very attractive area for investors.

Chinese healthcare is still in its infancy. As figure 2 shows, healthcare spending in China is among the lowest in the world.

Figure 2: Per capita healthcare expenditure vs per capita GDP

Four growth trends in China

1. Policy support: the government’s Healthy China 2030 plan aims to grow the sector to RMB 8 trillion revenue by 2020 (some USD 1.25 trillion), implying a 15% compounded annual growth rate (figure 3). The reform of China’s healthcare system is aimed at cutting drug prices, encouraging innovation and increasing healthcare capacity.

Figure 3: Chinese healthcare market size

Source: China National Pharmaceutical Industry Information Center

2. Demographic change: a growing middle class can afford healthcare, while at the same time the aging population pushes up demand.

3. Rise in chronic diseases, such as hypertension and diabetes, naturally increasing demand.

4. Broadening insurance coverage: as most Chinese now have some form of insurance, they are more likely to use healthcare services.

Be selective

Over the past five years, the MSCI China Healthcare index has outperformed the MSCI China index by 27% per year. The leading players are gaining share, at a compounded annual growth rate (CAGR) of some 20%. Although valuations have risen somewhat, they are still reasonable.

Going forward, it’s not simply the tide raising all boats anymore. With some short-term headwinds, it’s key to be selective. Up until now, government spending on the healthcare sector has been huge, but this is likely to slow.

We like leading chemical and biological companies with innovation and R&D capabilities. On the other end of the spectrum, manufacturers of over-the-counter traditional Chinese medicine, such as nutrition supplements, are also attractive. The latter play into the Chinese’ increasing health awareness, are becoming more affordable and are deemed safer than chemical drugs by 73% of the Chinese population.

Subjects related to this article are:

Disclaimer

Please read this important information before proceeding further. It contains legal and regulatory notices relevant to the information contained on this website.

The information contained in the Website is NOT FOR RETAIL CLIENTS - The information contained in the Website is solely intended for professional investors, defined as investors which (1) qualify as professional clients within the meaning of the Markets in Financial Instruments Directive (MiFID), (2) have requested to be treated as professional clients within the meaning of the MiFID or (3) are authorized to receive such information under any other applicable laws. The value of the investments may fluctuate. Past performance is no guarantee of future results. Investors may not get back the amount originally invested. Neither Robeco Institutional Asset Management B.V. nor any of its affiliates guarantees the performance or the future returns of any investments. If the currency in which the past performance is displayed differs from the currency of the country in which you reside, then you should be aware that due to exchange rate fluctuations the performance shown may increase or decrease if converted into your local currency.

In the UK, Robeco Institutional Asset Management B.V. (“ROBECO”) only markets its funds to institutional clients and professional investors. Private investors seeking information about ROBECO should visit our corporate website www.robeco.com or contact their financial adviser. ROBECO will not be liable for any damages or losses suffered by private investors accessing these areas.

In the UK, ROBECO Funds has marketing approval for the funds listed on this website, all of which are UCITS funds. ROBECO is authorized by the AFM and subject to limited regulation by the Financial Conduct Authority. Details about the extent of our regulation by the Financial Conduct Authority are available from us on request.

Many of the protections provided by the United Kingdom regulatory framework may not apply to investments in ROBECO Funds, including access to the Financial Services Compensation Scheme and the Financial Ombudsman Service. No representation, warranty or undertaking is given as to the accuracy or completeness of the information on this website.

If you are not an institutional client or professional investor you should therefore not proceed. By proceeding please note that we will be treating you as a professional client for regulatory purposes and you agree to be bound by our terms and conditions.

If you do not accept these terms and conditions, as well as the terms of use of the website, please do not continue to use or access any pages on this website.

I Disagree